Which has stronger valuation and earnings, MPLT or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is MPLT or ELYM more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Eliem Therapeutics N/A -47.03% -45.97%

Do analysts rate SEPN or ELYM?

Septerna presently has a consensus target price of $45.89, indicating a potential upside of 34.97%. Given Septerna's stronger consensus rating and higher probable upside, analysts plainly believe Septerna is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer ELYM or AVLN?

Avalyn Pharma has a consensus target price of $59.00, suggesting a potential upside of 98.45%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avalyn Pharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20

Which has better earnings and valuation, ELYM or AVLN?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A Avalyn Pharma N/A N/A N/A -$21.83 N/A

Is ELYM or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Avalyn Pharma N/A N/A N/A

Do analysts rate ELYM or KALV?

KalVista Pharmaceuticals has a consensus price target of $30.60, suggesting a potential upside of 13.33%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 KalVista Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22

Is ELYM or KALV more profitable?

Eliem Therapeutics' return on equity of -47.03% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% KalVista Pharmaceuticals N/A -341.44% -111.94%

Do analysts prefer ELYM or MLTX?

MoonLake Immunotherapeutics has a consensus target price of $24.21, indicating a potential upside of 27.78%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MoonLake Immunotherapeutics 3 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.41

Which has higher valuation and earnings, ELYM or MLTX?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is ELYM or MLTX more profitable?

Eliem Therapeutics' return on equity of -47.03% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Eliem Therapeutics (ELYM) Competitors

$12.90 -0.39 (-2.93%)

As of 07/2/2026

Compare

ELYM vs. MPLT, SEPN, AVLN, KALV, and MLTX

Should you buy Eliem Therapeutics stock or one of its competitors? MarketBeat compares Eliem Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eliem Therapeutics include Maplight Therapeutics (MPLT), Septerna (SEPN), Avalyn Pharma (AVLN), KalVista Pharmaceuticals (KALV), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

How does Eliem Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Maplight Therapeutics had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for Maplight Therapeutics and 0 mentions for Eliem Therapeutics. Maplight Therapeutics' average media sentiment score of 0.60 beat Eliem Therapeutics' score of 0.00 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Maplight Therapeutics	Positive
Eliem Therapeutics	Neutral

Maplight Therapeutics' return on equity of 0.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Eliem Therapeutics	N/A	-47.03%	-45.97%

Maplight Therapeutics presently has a consensus target price of $38.80, suggesting a potential upside of 4.61%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Maplight Therapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

69.8% of Eliem Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Summary

Maplight Therapeutics beats Eliem Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Eliem Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Septerna presently has a consensus target price of $45.89, indicating a potential upside of 34.97%. Given Septerna's stronger consensus rating and higher probable upside, analysts plainly believe Septerna is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

69.8% of Eliem Therapeutics shares are held by institutional investors. 5.8% of Septerna shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Septerna has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market.

In the previous week, Septerna had 12 more articles in the media than Eliem Therapeutics. MarketBeat recorded 12 mentions for Septerna and 0 mentions for Eliem Therapeutics. Septerna's average media sentiment score of 0.09 beat Eliem Therapeutics' score of 0.00 indicating that Septerna is being referred to more favorably in the media.

Company	Overall Sentiment
Septerna	Neutral
Eliem Therapeutics	Neutral

Eliem Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Eliem Therapeutics has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Eliem Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	33.36	-$48.88M	-$0.81	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Summary

Septerna beats Eliem Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Eliem Therapeutics compare to Avalyn Pharma?

Eliem Therapeutics (NASDAQ:ELYM) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 equaled Avalyn Pharma'saverage media sentiment score.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Avalyn Pharma	Neutral

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

Avalyn Pharma's return on equity of 0.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Avalyn Pharma	N/A	N/A	N/A

Avalyn Pharma has a consensus target price of $59.00, suggesting a potential upside of 98.45%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Avalyn Pharma beats Eliem Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Eliem Therapeutics compare to KalVista Pharmaceuticals?

Eliem Therapeutics (NASDAQ:ELYM) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 equaled KalVista Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
KalVista Pharmaceuticals	Neutral

Eliem Therapeutics' return on equity of -47.03% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

KalVista Pharmaceuticals has a consensus price target of $30.60, suggesting a potential upside of 13.33%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eliem Therapeutics has higher earnings, but lower revenue than KalVista Pharmaceuticals. Eliem Therapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

Summary

Eliem Therapeutics and KalVista Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Eliem Therapeutics compare to MoonLake Immunotherapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

In the previous week, MoonLake Immunotherapeutics had 7 more articles in the media than Eliem Therapeutics. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 0 mentions for Eliem Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.47 beat Eliem Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
MoonLake Immunotherapeutics	Neutral

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Eliem Therapeutics' return on equity of -47.03% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MoonLake Immunotherapeutics has a consensus target price of $24.21, indicating a potential upside of 27.78%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Summary

MoonLake Immunotherapeutics beats Eliem Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELYM vs. The Competition

Export

Metric	Eliem Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$383.80M	$791.45M	$7.18B	$12.47B
Dividend Yield	N/A	4.84%	2.66%	6.51%
P/E Ratio	-24.34	1.66	28.02	24.70
Price / Sales	N/A	127.53	537.00	97.28
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	3.31	8.17	10.96	6.46
Net Income	-$35.12M	-$3.71M	$3.57B	$337.01M
7 Day Performance	-1.38%	2.59%	2.12%	1.69%
1 Month Performance	23.56%	4.41%	5.25%	3.81%
1 Year Performance	907.81%	49.43%	33.29%	23.90%

Eliem Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELYM Eliem Therapeutics	N/A	$12.90 -2.9%	N/A	+907.8%	$383.80M	N/A	N/A	9	High Trading Volume
MPLT Maplight Therapeutics	2.2595 of 5 stars	$36.08 +0.7%	$38.80 +7.5%	N/A	$1.53B	N/A	N/A	109
SEPN Septerna	2.5144 of 5 stars	$34.61 +3.3%	$45.89 +32.6%	+200.9%	$1.51B	$45.95M	N/A	N/A	News Coverage Analyst Forecast Insider Trade
AVLN Avalyn Pharma	3.6127 of 5 stars	$30.17 -8.4%	$59.00 +95.6%	N/A	$1.46B	N/A	N/A	51
KALV KalVista Pharmaceuticals	2.2512 of 5 stars	$27.00 flat	$30.60 +13.3%	N/A	$1.44B	$1.43M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELYM) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eliem Therapeutics (ELYM) Competitors

ELYM vs. MPLT, SEPN, AVLN, KALV, and MLTX

How does Eliem Therapeutics compare to Maplight Therapeutics?

Summary

How does Eliem Therapeutics compare to Septerna?

Summary

How does Eliem Therapeutics compare to Avalyn Pharma?

Summary

How does Eliem Therapeutics compare to KalVista Pharmaceuticals?

Summary

How does Eliem Therapeutics compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eliem Therapeutics (ELYM) Competitors

ELYM vs. MPLT, SEPN, AVLN, KALV, and MLTX

How does Eliem Therapeutics compare to Maplight Therapeutics?

Does the media favor MPLT or ELYM?

Is MPLT or ELYM more profitable?

Do analysts rate MPLT or ELYM?

Do insiders and institutionals hold more shares of MPLT or ELYM?

Which has stronger valuation and earnings, MPLT or ELYM?

Summary

How does Eliem Therapeutics compare to Septerna?

Do analysts rate SEPN or ELYM?

Do insiders and institutionals believe in SEPN or ELYM?

Which has more volatility and risk, SEPN or ELYM?

Does the media prefer SEPN or ELYM?

Is SEPN or ELYM more profitable?

Which has preferable earnings & valuation, SEPN or ELYM?

Summary

How does Eliem Therapeutics compare to Avalyn Pharma?

Does the media refer more to ELYM or AVLN?

Which has better earnings and valuation, ELYM or AVLN?

Is ELYM or AVLN more profitable?

Do analysts prefer ELYM or AVLN?

Do insiders & institutionals hold more shares of ELYM or AVLN?

Summary

How does Eliem Therapeutics compare to KalVista Pharmaceuticals?

Does the media refer more to ELYM or KALV?

Is ELYM or KALV more profitable?

Do analysts rate ELYM or KALV?

Which has more volatility and risk, ELYM or KALV?

Do insiders and institutionals have more ownership in ELYM or KALV?

Which has stronger earnings & valuation, ELYM or KALV?

Summary

How does Eliem Therapeutics compare to MoonLake Immunotherapeutics?

Does the media refer more to ELYM or MLTX?

Which has more risk & volatility, ELYM or MLTX?

Which has higher valuation and earnings, ELYM or MLTX?

Is ELYM or MLTX more profitable?

Do insiders and institutionals hold more shares of ELYM or MLTX?

Do analysts prefer ELYM or MLTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools